ACT UP and their colleagues fought for nine years before winning life-saving medications. They organized a mass movement, they took to the streets, they made art, they made noise, they made a difference. Their tools included clear demands, arresting graphics, media savvy, and an ability to learn from their mistakes and refine their strategies. And […]
The POLITICO Pro Health care team takes an in-depth look at the future and policies of the FDA. Special guests include: Friends of Cancer Research’s Dr. Jeff Allen; The Pew Charitable Health Group’s Allan Coukell; Biotechnology Industry Organization’s Sara Radcliffe and the FDA’s Dr. Janet Woodcock.
On September 25, 2012, the President’s Council of Advisors on Science and Technology (“PCAST”) released a report entitled “Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation.”
Christopher P. Austin, M.D., named director of NCATS The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases […]
Rare disease advocate says the focus should be on ensuring the accelerated approval expansion and surrogate endpoint guidances become FDA priorities as the rare disease drug program is set to grow under PDUFA V. By Derrick Gingery / Email the Author / “The Pink Sheet” Sep. 17, 2012, Vol. 74, No. 38 Regulatory Update / […]
BY ELIZABETH M. WROE & PHILIP S. BONFORTE The threat of a delayed or deterred (re-)authorization of key Food and Drug Administration (FDA) user fee programs (hereinafter referred to as the ‘‘FDA user fees’’) caused significant angst among biomedical product stakeholders over the course of the last year and a half.
Politics » Utahn Jamie Hartley says nobody was more surprised than she that her politics leaned left. by: By Matt Canham| The Salt Lake Tribune Washington • Of all the Utahns elected as delegates to the Democratic National Convention, Jamie Hartley is the outlier. She isn’t a party insider or union leader, a politician or a […]
By Kurt R. Karst – Just before Congress recessed for the month of August, and less than a month after the July 9th enactment of the FDA Safety and Innovation Act, several FDA-related bills were placed in the hoppers in the U.S. Senate and U.S. House of Representatives. With an election on the horizon and several other […]
From the EveryLife Foundation for Rare Diseases: FOR IMMEDIATE RELEASE Obama Signs FDA User Fee Legislation Bringing Hope to Rare Disease Patients EveryLife Foundation for Rare Diseases Applauds Congress for Including Provision to Empower the FDA to Accelerate Approval of Lifesaving Treatments
SENS. SHERROD BROWN, ROGER WICKER INTRODUCE BIPARTISAN LEGISLATION to Strengthen and Expand Pediatric Research Despite Children Making Up 20 Percent of the U.S. Population, Just Five Percent of NIH’s Research is Dedicated to Pediatric Research; National Pediatric Research Network Act Expands NIH’s Investments into Pediatric Research, Including Rare Diseases